• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nyxoah SA

    3/20/25 4:26:06 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email
    S-8 1 tm258421d1_s8.htm FORM S-8

    As filed with the Securities and Exchange Commission on March 20, 2025

    Registration No. 333-    

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549

     

     

    FORM S-8

     

     

    REGISTRATION STATEMENT UNDER

     

    THE SECURITIES ACT OF 1933

     

     

    NYXOAH SA

    (Exact name of registrant as specified in its charter)

     

     

    Belgium
    (State or other jurisdiction of incorporation
    or organization)
      Not Applicable
    (I.R.S. Employer Identification No.)

     

    Rue Edouard Belin 12

    1435 Mont-Saint-Guibert, Belgium
    (Address of principal executive offices)

     

    2025 Warrants Plan

    (Full title of the plans)

     

    Corporation Service Company

    1090 Vermont Avenue N.W.

    Washington D.C. 20005

    United States

    Telephone: +1 800 927 9800

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    John T. Rudy, Esq.

    Jason S. McCaffrey, Esq.

    Mintz, Levin, Cohn, Ferris,

    Glovksy & Popeo, P.C.

    One Financial Center

    Boston, MA 02111

    (617) 542 6000

    Philippe Remels

    NautaDutilh

    BV/SRL

    Chaussée de La Hulpe 120

    1000 Brussels, Belgium

    +32 2 566 80 00

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer x
    Non-accelerated filer ¨ Smaller reporting company ¨
      Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    PART I.

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated herein by reference:

     

    (a)       the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on March 20, 2025;

     

    (b)       the Registrant’s Current Reports on Form 6-K furnished to the Commission on January 2, 2025 and March 13, 2025 (other than portions of the foregoing expressly excluded from incorporation by reference) (No. 001-40552); and

     

    (c)       the description of the Registrant’s Ordinary Shares which is contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-40552) filed with the Commission on June 28, 2021, including any amendment or report filed for the purpose of updating such description.

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents (the “Incorporated Documents”).

     

    Any statement contained herein or in any Incorporated Document shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained in any subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable

     

    Item 6. Indemnification of Directors and Officers.

     

    Under Belgian law, the directors of a company may be liable for damages to the company in case of improper performance of their duties. The Registrant’s directors may be liable to the Registrant and to third parties for infringement of the Registrant’s articles of association or Belgian company law. Under certain circumstances, directors may be criminally liable.

     

    The Registrant maintains liability insurance for the Registrant’s directors and officers, including insurance against liability under the Securities Act.

     

    The New Belgian Companies Code that entered into force on January 1, 2020, includes a cap on liability for directors (including persons in charge of daily management) for any damages they cause due to mismanagement, including breaches of the articles of association and the New Belgian Companies Code. This liability cap applies towards the company and third parties. For the Registrant, the cap amounts to €12,000,000. The cap applies irrespective of the number of claimants or defendants for the same (set of) facts. However, the cap does not apply to repetitive minor misconduct, serious error or cases of fraud. Furthermore, the cap does not apply to directors’ liability under the special liability regimes relating to payment of withholding tax, VAT and social security contributions.

     

     

     

     

    Certain of the Registrant’s non-executive directors may, through their relationships with their employers or partnerships, be insured and/or indemnified against certain liabilities in their capacity as members of the Registrant’s board of directors.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Exhibit Description     Incorporated by
    Reference herein
    from Form or
    Schedule
      Filing Date   SEC File/
    Reg.
    Number
    4.1   Articles of Association, as amended (English Translation)     20-F (Exhibit 1.1)   March 20, 2025   001-40552
    5.1*   Opinion of NautaDutilh BV/SRL              
    23.1*   Consent of EY Réviseurs d’Entreprises / EY Bedrijfsrevisoren SRL/BV, independent registered public accounting firm              
    23.2*   Consent of NautaDutilh BV/SRL (included in Exhibit 5.1)              
    24.1*   Power of Attorney (included on the signature page hereto)              
    99.1*   Form of 2025 Warrants Plan (English Translation)              
     107*   Filing Fee Table              
    *Filed herewith                  

     

    Item 9. Undertakings.

     

    1. The undersigned Registrant hereby undertakes:

     

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

     

     

     

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mont-Saint-Guibert, Belgium, on the 20th day of March, 2025.

     

      NYXOAH SA
       
      By: /s/ Olivier Taelman
        Olivier Taelman
        Chief Executive Officer

     

    SIGNATURES AND POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each of the directors and officers of Nyxoah SA, whose signature appears below hereby severally constitutes and appoints Olivier Taelman and John Landry, and each of them singly, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Nyxoah SA, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their substitute may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Olivier Taelman  

    Chief Executive Officer and Director

    (principal executive officer)

      March 20, 2025
    Olivier Taelman    
             
    /s/ John Landry   Chief Financial Officer (principal accounting officer and principal financial officer)   March 20, 2025
    John Landry    
             
    /s/ Robert Taub   Chairman of the Board of Directors   March 20, 2025
    Robert Taub, acting via Robelga SRL        
             
    /s/ Kevin Rakin   Director   March 20, 2025
    Kevin Rakin        
             
    /s/ Jürgen Hambrecht   Director   March 20, 2025
    Jürgen Hambrecht        
             
    /s/ Pierre Gianello   Director   March 20, 2025
    Pierre Gianello        
             
    /s/ Rita Johnson-Mills   Director   March 20, 2025
    Rita Johnson-Mills        
             
    /s/ Virginia Kirby   Director   March 20, 2025
    Virginia Kirby        
             
    /s/ Daniel Wildman   Director   March 20, 2025
    Daniel Wildman, acting via Wildman Ventures LLC        

     

     

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Nyxoah SA, has signed this registration statement on Form S-8 on March 20, 2025.

     

      NYXOAH, INC.
       
      By: /s/ Olivier Taelman
      Name: Olivier Taelman
      Title: Chief Executive Officer, President and Secretary

     

     

    Get the next $NYXH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings

    $NYXH
    SEC Filings

    View All

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    12/5/25 4:05:05 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Nyxoah SA

    424B5 - Nyxoah SA (0001857190) (Filer)

    11/17/25 6:30:30 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    11/14/25 4:05:07 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Publication relating to transparency notifications

                     REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Robert Taub / BMI Estate On November 27, 2025, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,290,800 voting rights, consisting of 4,240,800 voting rights linked to securities

    12/2/25 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference

    Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast. A live audio webcast of the presentation will be available online at the investor relations page o

    11/27/25 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

    Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has finalized its CY2026 Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory

    11/26/25 1:45:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Nyxoah S.A.

    H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy

    7/31/23 8:05:01 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Robert W. Baird initiated coverage on Nyxoah S.A.

    Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral

    7/19/23 7:19:37 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Nyxoah S.A. with a new price target

    Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00

    4/21/22 7:16:59 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Financials

    Live finance-specific insights

    View All

    Nyxoah Reports Third Quarter 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2025. Recent Financial and Operating Highlights Completed the first commercial implants of U.S. patients, and genera

    11/13/25 4:12:11 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

    Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through t

    10/30/25 5:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Reports Second Quarter Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hyp

    8/18/25 4:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Leadership Updates

    Live Leadership Updates

    View All

    Nyxoah Appoints John Landry as Chief Financial Officer

    Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry

    11/4/24 4:45:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by

    7/15/24 2:00:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Strengthens its Executive Leadership Team

    Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device

    11/28/23 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nyxoah SA

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    10/10/24 4:00:17 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Nyxoah SA (Amendment)

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    5/30/24 5:20:40 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

    SC 13G/A - Nyxoah SA (0001857190) (Subject)

    2/14/24 4:17:59 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care